Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Core Insights - Marker Therapeutics, Inc. provided an update on the Phase 1 APOLLO study for MT-601, a Multi-Antigen Recognizing (MAR)-T cell product, targeting lymphoma patients who have relapsed after anti-CD19 CAR-T therapy or are not candidates for it [1][2] Efficacy and Response - The study reported a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving a complete response [2][4] - Among 12 NHL patients treated, 8 showed objective responses, and 6 had a complete response, with durable responses lasting from 3 to 24 months [4] - In Hodgkin Lymphoma (HL) patients, 78% had objective responses, with one patient achieving a complete response [5] Safety Profile - The dose escalation study tested doses from 100×10^6 to 400×10^6 cells, showing no dose-limiting toxicities at the highest dose [6] - MT-601 was well tolerated, with no serious adverse events reported, and only two Grade 1 cytokine release syndrome events observed [6][7] - No differences in safety were noted between patients treated with or without lymphodepleting chemotherapy [7] Future Outlook - The company plans to provide another data update in the first half of 2026 [7]